Loading...
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are highly heterogeneous myeloid diseases, characterized by frequent genetic/chromosomal aberrations. Olaparib is a potent, orally bioavailable poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with acceptable toxicity profile, designed as targeted therapy for DNA repai...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6769925/ https://ncbi.nlm.nih.gov/pubmed/31527467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091373 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|